e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Asthma: risk factors and effect of anti-IgE
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of omalizumab in real-life practice in India
A. Mahashur, D. Talwar, M. Kotnis (Mumbai, Noida, India)
Source:
Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Session:
Asthma: risk factors and effect of anti-IgE
Session type:
Poster Discussion
Number:
229
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Mahashur, D. Talwar, M. Kotnis (Mumbai, Noida, India). Efficacy and safety of omalizumab in real-life practice in India. Eur Respir J 2012; 40: Suppl. 56, 229
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Pavic Michelle - 02.09.2012 11:50
Hello, would it be possible to get a copy of your poster emailed to michelle.pavic@novartis.com? I have found the data to be quite interesting. Thanks.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Italian real-life experience of omalizumab
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine
Source: Virtual Congress 2021 – Cystic fibrosis
Year: 2021
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019
A post-marketing study to evaluate the safety and tolerability of a non-chlorofluorocarbon salbutamol inhaler in asthmatic patients in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 78s
Year: 2002
Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
Year: 2018
Clinical efficacy and safety of medical thoracoscopy
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Clinical and economic outcomes following 52-week add-on omalizumab
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2015; 45: 161-170
Year: 2015
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2016; 47:1591-1592
Year: 2016
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006
Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care
Source: Annual Congress 2010 - Pharmacological treatment in primary care
Year: 2010
Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies?
Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis
Year: 2019
Use of Omalizumab in children in real clinical practice.
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept